1.A Pediatric Case of a D-Penicillamine Induced ANCA-associated Vasculitis Manifesting a Pulmonary-Renal Syndrome
Sena KANG ; Myung Hyun CHO ; Hyesun HYUN ; Ji Hyun KIM ; Jae Sung KO ; Hee Gyung KANG ; Hae Il CHEONG ; Woo Sun KIM ; Kyung Chul MOON ; Il Soo HA
Journal of Korean Medical Science 2019;34(24):e173-
D-penicillamine has been reported to cause antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis presenting as rapidly progressive glomerulonephritis or pulmonary-renal syndrome mostly in adults. We report a pediatric case of D-penicillamine induced ANCA-associated vasculitis that manifests as a pulmonary-renal syndrome with a mild renal manifestation. A 13-year-old girl who has been taking D-penicillamine for five years under the diagnosis of Wilson disease visited the emergency room because of hemoptysis and dyspnea. She had diffuse pulmonary hemorrhage, microscopic hematuria, and proteinuria. Myeloperoxidase ANCA was positive, and a renal biopsy revealed pauci-immune crescentic glomerulonephritis. Under the diagnosis of D-penicillamine-induced ANCA-associated vasculitis, D-penicillamine was switched to trientine, and the patient was treated with plasmapheresis, glucocorticoid, cyclophosphamide, and mycophenolate mofetil. Pulmonary hemorrhage improved rapidly followed by the disappearance of the hematuria and proteinuria five months later.
Adolescent
;
Adult
;
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
;
Antibodies, Antineutrophil Cytoplasmic
;
Biopsy
;
Child
;
Cyclophosphamide
;
Diagnosis
;
Dyspnea
;
Emergency Service, Hospital
;
Female
;
Glomerulonephritis
;
Hematuria
;
Hemoptysis
;
Hemorrhage
;
Hepatolenticular Degeneration
;
Humans
;
Penicillamine
;
Peroxidase
;
Plasmapheresis
;
Proteinuria
;
Trientine
;
Vasculitis
2.Growth Differentiation Factor 15 Expression in Astrocytes After Excitotoxic Lesion in the Mouse Hippocampus.
Min Hee YI ; Enji ZHANG ; Hyunjung BAEK ; Sena KIM ; Nara SHIN ; Joon Won KANG ; Sunyeul LEE ; Sang Ha OH ; Dong Woon KIM
Experimental Neurobiology 2015;24(2):133-138
Growth differentiation factor 15 (GDF15) is, a member of the transforming growth factor beta (TGF-beta) superfamily of proteins. Although GDF15 is well established as a potent neurotrophic factor for neurons, little is known about its role in glial cells under neuropathological conditions. We monitored GDF15 expression in astrocyte activation after a kainic acid (KA)-induced neurodegeneration in the ICR mice hippocampus. In control, GDF15 immunoreactivity (IR) was evident in the neuronal layer of the hippocampus; however, GDF15 expression had increased in activated astrocytes throughout the hippocampal region at day 3 after the treatment with KA. LPS treatment in astrocytes dramatically increased GDF15 expression in primary astrocytes. In addition, LPS treatment resulted in the decrease of the IkappaB-alpha degradation and increase of the phosphorylation level of RelA/p65. These results indicate that GDF15 has a potential link to NF-kappaB activation, making GDF15 a valuable target for modulating inflammatory conditions.
Animals
;
Astrocytes*
;
Growth Differentiation Factor 15*
;
Hippocampus*
;
Kainic Acid
;
Mice*
;
Mice, Inbred ICR
;
Neuroglia
;
Neurons
;
NF-kappa B
;
Phosphorylation
;
Transforming Growth Factor beta
3.Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes.
Eun Young LEE ; Sena HWANG ; Yong Ho LEE ; Seo Hee LEE ; Young Mi LEE ; Hua Pyong KANG ; Eugene HAN ; Woonhyoung LEE ; Byung Wan LEE ; Eun Seok KANG ; Bong Soo CHA ; Hyun Chul LEE
Yonsei Medical Journal 2017;58(2):312-318
PURPOSE: Metformin can reduce diabetes-related complications and mortality. However, its use is limited because of potential lactic acidosis-associated adverse effects, particularly in renal impairment patients. We aimed to investigate the association of metformin use with lactic acidosis and hyperlactatemia in patients with type 2 diabetes. MATERIALS AND METHODS: This was a cross-sectional study from a tertiary university-affiliated medical center. A total of 1954 type 2 diabetes patients were recruited in 2007–2011, and stratified according to the estimated glomerular filtration rate of 60 mL/min/1.73 m2. Lactic acidosis was defined as plasma lactate levels >5 mmol/L and arterial pH <7.35. RESULTS: Metformin was used in 61.4% of the patients with type 2 diabetes mellitus. Plasma lactate levels were not different in the patients with and without metformin use. There was no difference in prevalence of hyperlactatemia and lactic acidosis between the patients with and without metformin use (18.9% vs. 18.7%, p=0.905 for hyperlactatemia and 2.8% vs. 3.3%, p=0.544 for lactic acidosis). Similar results were observed in the patients with estimated glomerular filtration rate <60 mL/min/1.73 m². Most patients with lactic acidosis had at least one condition related to hypoxia or poor tissue perfusion. Multiple regression analysis indicated no association between metformin use and lactic acidosis, whereas tissue hypoxia was an independent risk factor for lactic acidosis [odds ratio 4.603 (95% confidence interval, 1.327–15.965)]. CONCLUSION: Metformin use was not associated with hyperlactatemia or lactic acidosis in patients with type 2 diabetes.
Acidosis, Lactic*
;
Anoxia
;
Cross-Sectional Studies
;
Diabetes Complications
;
Diabetes Mellitus
;
Diabetes Mellitus, Type 2
;
Glomerular Filtration Rate
;
Humans
;
Hydrogen-Ion Concentration
;
Hyperlactatemia
;
Lactic Acid*
;
Metformin*
;
Mortality
;
Perfusion
;
Plasma
;
Prevalence
;
Risk Factors
4.Bariatric surgery versus medical therapy in Korean obese patients: prospective multicenter nonrandomized controlled trial (KOBESS trial)
Do Joong PARK ; Sena AN ; Young Suk PARK ; Joo-Ho LEE ; Hyuk-Joon LEE ; Tae Kyung HA ; Yong-Jin KIM ; Seung-Wan RYU ; Sang-Moon HAN ; Moon-Won YOO ; Sungsoo PARK ; Sang-Uk HAN ; Jae-Heon KANG ; Jin-Won KWON ; Yoonseok HEO
Annals of Surgical Treatment and Research 2021;101(4):197-205
Purpose:
The aim of this study was to show that bariatric surgery (BS) is more effective than medical therapy (MT) in Asian obese patients.
Methods:
In this prospective, multicenter, nonrandomized, controlled trial, obese patients with body mass index of ≥35 kg/m2 or 30.0–34.9 kg/m2 with obesity-related comorbidities were assigned to undergo BS, such as laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass, or MT. Patients who underwent BS were evaluated 4, 12, 24, and 48 weeks after surgery, whereas patients who received MT were monitored at a hospital every 6 weeks for 1 year. At each visit, weight, waist and hip circumference, and blood pressure were measured, and patients underwent physical examination and laboratory testing. Health-related quality of life (HQOL) was investigated using Euro QOL-5 Dimension, Impact of Weight on Quality of Life questionnaire-Lite and Obesity-related Problems scale.
Results:
The study included 264 patients from 13 institutions; of these, 64 underwent BS and 200 received MT. Of the patients who underwent BS, 6.3% experienced early complications. Relative weight changes from baseline to 48 weeks were significantly greater in the BS than in the MT group (26.9% vs. 2.1%, P < 0.001), as were the rates of remission of diabetes (47.8% vs. 16.7%, P = 0.014), hypertension (60.0% vs. 26.1%, P < 0.001), and dyslipidemia (63.2% vs. 22.0%, P < 0.001). HQOL was better in the BS than in the MT group at 48 weeks.
Conclusion
BS was safe and effective in Korean obese patients, with greater weight reduction, remission of comorbidities, and quality of life improvement than MT.